Co-founder and executive Chairman of the Board of directors, Dr. Mads Daugaard, are to present data on VAR2-based immunotherapy in the context of the cancer microenvironemnt at the 9th CDD Conference on Cancer, taking place in London, September 17-19, 2018. The title of the talk is “Targeting oncofetal glycosaminoglycans in the tumor microenvironment”.
VarCT Diagnostics/VAR2 Pharmaceuticals will be at the Nordic Life Science Days in Stockholm 10-12 September 2018. We look forward to meet old and new partners in the Life Science business.
Today our researchers at Copenhagen University and University of British Columbia together with academic partners in United Kingdom, Australia and Taiwan published an article in Nature Communications that demonstrates that rVAR2 indeed can be used as a tool to capture and isolate circulating tumour cells (CTCs) of various types. This is an important event also […]
Check out the article about VAR2 Pharmaceuticals and VarCT Diagnostics here.
VAR2 Pharmaceuticals founder and member of the Board of Directors, Prof. Poul Sorensen, will give a talk with the title “Probing the surface proteome for immunotherapy targets in high-risk pediatric cancers” on Saturady April 14th at the AACR meeting in Chicago, IL. The presentation will highlight some aspects of relevance for the VAR2 technology. See this link for […]
New significant data about chondroitin sulphate – the target for the VAR2 protein – in prostate cancer, will be presented on April 18th, at this year’s AACR meeting in Chicago, IL. The work is presented in a poster entitled “Expression and regulation of chondroitin sulfate in prostate cancer” and is the result of work by […]
VAR2 Pharmaceuticals will take part in the 23rd annual BIO-Europe partnering conference, 6-8 November 2017, in Berlin. With a full meeting schedule we look forward to have many fruitful discussions with potential partners in the pharma and biotech industry. See you there!
We are very happy to today announce the foundation of VarCT Diagnostics ApS, a sister company to VAR2 Pharmaceuticals. VarCT Diagnostics will, based on our proprietary malaria protein, focus on the development of a universal tool to capture circulating tumour cells (CTC) as means for diagnosis, prognosis and monitoring of cancer during treatment. The transfer of the […]
We are very happy to today announce the foundation of VarCT Diagnostics ApS, a sister company to VAR2 Pharmaceuticals. VarCT Diagnostics will, based on our proprietary malaria protein, focus on the development of a universal tool to capture circulating tumour cells (CTC) as means for diagnosis, prognosis and monitoring of cancer during treatment. The transfer of the […]
It is with great pleasure that VAR2 Pharmaceuticals can announce that our first patent has been issued by the Australian Government (IP Australia). Key claims on the use of recombinant VAR2CSA for targeting, treating and diagnosing cancer was accepted and issued.
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.